000			02094nam a22003737a 4500
008			170417s20162016 xxu||||| |||| 00| 0 eng d
022			_a0394-6320
040			_aOvid MEDLINE(R)
099			_a25816416
245			_aThe possible role of glutathione-S-transferase activity in diabetic nephropathy. [Review]
251			_aInternational Journal of Immunopathology & Pharmacology. 28(1):129-33, 2015 Mar
252			_aINT. J. IMMUNOPATHOL. PHARMACOL.. 28(1):129-33, 2015 Mar
253			_aInternational journal of immunopathology and pharmacology
260			_c2015
260			_fFY2015
266			_d2017-05-06
520			_aCopyright © The Author(s) 2015.
520			_aThe most common cause of end stage renal disease is diabetic nephropathy. An early diagnosis may allow an intervention to slow down disease progression. Recently, it has been hypothesized that glutathione-S-transferase (GST) activity may be a marker of severity of chronic kidney disease. In particular, a lower GST activity is present in healthy subjects compared to patients with nephropathy. In the present review we illustrate the scientific evidence underlying the possible role of GST activity in the development of diabetic nephropathy and we analyze its usefulness as a possible early biomarker of this diabetic complication.
546			_aEnglish
650			_a*Diabetes Complications/me [Metabolism]
650			_a*Diabetic Nephropathies/me [Metabolism]
650			_a*Glutathione Transferase/me [Metabolism]
650			_aBiomarkers/me [Metabolism]
650			_aHumans
650			_aKidney Failure, Chronic/me [Metabolism]
650			_aRenal Insufficiency, Chronic/me [Metabolism]
651			_aMedStar Heart & Vascular Institute
657			_aLetter
657			_aReview
700			_aCampia, Umberto
790			_aCampia U, Cardillo C, Costa A, Di Cola G, Di Daniele N, Lauro D, Marrone G, Nistico S, Noce A, Rovella V, Tarantino A, Tesauro M
856			_uhttps://dx.doi.org/10.1177/0394632015572564 _zhttps://dx.doi.org/10.1177/0394632015572564
942			_cART _dArticle
999			_c2111 _d2111